Af­ter mixed pipeline up­dates, Re­genXBio to raise $175M in of­fer­ing; Bio­Elec­tron clos­es $40M to prep late-stage mi­to­chon­dr­i­al drug

→ Just a cou­ple days af­ter an­nounc­ing some mixed pipeline up­dates that yo-yoed the stock, gene ther­a­py com­pa­ny Re­genXBio $RGNX is trot­ting out news of a stock of­fer­ing to­tal­ing $175 mil­lion. The pa­per­work was ac­tu­al­ly filed on the same day as their pipeline up­dates, which could have con­tributed to in­vestors’ mood­i­ness ear­li­er this week. The Rockville, MD-based com­pa­ny plans to sell 2.7 mil­lion shares of its com­mon stock at $65 per share. That’s about fair, as the com­pa­ny’s stock price is hov­er­ing around that mark Fri­day morn­ing. Pro­ceeds, in part, are go­ing to­wards the com­pa­ny’s pipeline of in­ves­ti­ga­tion­al ther­a­pies, in­clud­ing RGX-314, RGX-501, RGX-111, and RGX-121, ac­cord­ing to the com­pa­ny’s SEC state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.